TORONTO, April 13, 2018 /PRNewswire/ – Beleave Inc. (“Beleave” or the “Company“) (CSE: BE; OTCQX: BLEVF) is pleased to announce that its wholly-owned subsidiary, Beleave Kannabis Corp., has received its sales license from Health Canada pursuant to the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“).
“We are thrilled to have obtained our sales license from Health Canada,” stated Beleave CEO, Andrew Wnek. “We have remained diligent and focused throughout the process. We are excited to be able to continue to move the company forward as a result of this news.”
The Company also announces that it has granted 200,000 stock options to purchase common shares (the “Options“) to certain members of its board of directors (the “Board“) in accordance with the Company’s stock option plan. Each option is exercisable to purchase one common share of the Company at $3.00 per common share. All Options vest immediately and expire on January 3, 2021. All common share and option issuances are subject to applicable regulatory approvals (including the Canadian Securities Exchange).
Beleave Inc. is a biotech company and Beleave’s wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave’s purpose-built facility is located in Hamilton, Ontario.